Does South Korea Need A State-Owned Pharma To Stabilize Supply?
This article was originally published in PharmAsia News
Executive Summary
South Korea repeatedly faced drug supply disruptions when dealing with the outbreak of bird flu and new influenza, and when pharma firms refused to produce inexpensive but essential medicines, or drugs for rare diseases, due to low profitability. A local research paper now says the country may need a state-run pharma to ensure stable future supplies of essential medicines.
You may also be interested in...
Korea Lays Essential Drug Plans Amid Ongoing Supply Concerns
South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.
Thailand's Cost Control Measures And What They Mean For Pharma - IMS Analysis
SHANGHAI - Thailand's recent clampdown on public healthcare spending means multinational drug makers will have to look for news ways to tap the country's drug market, according to IMS Health
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.